In the AMPLIFIED study (phase 3, single-blind RCT) ABA not superior to ADA in patients with dual seropositive early RA and HLA Class II #ACR24 @RheumNow ABST#2671 https://t.co/VSorAiJUIe

Difficult to Manage Axial Spondyloarthritis Axial spondyloarthritis (axSpA) is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing back pain, stiffness, and reduced mobility. #ACR24 https://t.co/5i5QtJJm16 https://t.co/c4bllA8ngJ

SELECT-GCA suggests JAKis may be the new kid on the block Clinicians treating giant cell arteritis (GCA) have long had to contend with a disappointingly limited selection of drugs from which to select. https://t.co/vtJzwFZMBq https://t.co/dikMRwjIZY

Is Pregnancy Truly the Solution for RA? Pregnancy is perhaps the oldest treatment in rheumatoid arthritis (RA) and has been associated with a natural improvement in disease control in 50-75% of patients. Others, however, are not as successful with unchanged disease activity or… https://t.co/MesVIUl0fC https://t.co/760i5znmeu

💊Dapirolizumab (DZP) is a novel CD40L inhibitor 💊Results from phase 3 trial in #SLE 💊Demonstrated improvement in disease activity & GC tapering 💊More pts on DZP achieved BICLA response vs PBO 💊DZP well tolerated AbL16 #ACR24 @RheumNow https://t.co/dtb8QFKvlN

Dapirolizumab pegol (DZP) a novel drug wc inhibits CD40L signalling. In the PHOENYCS GO trial, pts on DZP+SOC achieved BICLA response at wk 48 vs. DZP+PBO -observed efficacy in SRI4, SLEDAI2K, LLDAS, BILAG -reduxn in steroid dose -well tolerated @RheumNow #ACR24 abL16 #ACRBest https://t.co/5tj2uwqeUz

Allogenic CD19 CAR-NK cells in SLE, experience w/22 pts 68% LLDAS remission, no relapse As with others, B cell reconstitution w/naive B cells & surprising safety (only 2 cases low-grade CRS) Lots of potential; still figuring out the particulars #ACR24 @RheumNow Abstr#L17 https://t.co/zLtMNrXIlX

LEVI-04 a novel neurotropin3-i showed: -significant analgesia across all measures -improvement in functional measures and PGA for all doses in a Ph2 RCT - well tolerated Hopefully will prove to be a therapeutic option for knee #osteoarthritis in future @RheumNow #ACR24 absL15 https://t.co/kWsyyyGxyU

Late breaking abstract L19 Study on the efficacy & safety of Emapalumab in treating Macrophage Activation Syndrome (MAS) in Still's Disease. Key findings: - 53.8% achieved complete response (CR) at Week 8; 85% at any time. - Rapid reduction in hyperinflammation biomarkers… https://t.co/VcmUdRP6PV https://t.co/r7AMt0IjYk

Grom et al. Emapalumab (anti-IFNg) in MAS in Stills. 39 patient pooled analysis. 54% complete response at week 8, 85% at any time. Clinically meaningful glucocorticoid reduction in 72%. @RheumNow #ACR24 Abstr#L19 https://t.co/U72KCfsUh7 https://t.co/jNxsvhseVf